Clinical Trials Logo

Cancer of Unknown Origin clinical trials

View clinical trials related to Cancer of Unknown Origin.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03628079 Terminated - Clinical trials for Cancer of the Gastrointestinal Tract

A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

RepoMeb
Start date: May 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of mebendazole (ReposMBZ) in patient with advanced gastrointestinal cancer or cancer of unknown origin. All patients will be given ReposMBZ for 16 weeks continuous treatment, individually dosed based on the serum concentration of mebendazole.